VINCOV-19, country’s first anti-dote for COVID, ready for

trials were conducted across multiple centres in the country involving over 200 patients and were completed in September. These trials also included testing the antidote against the Omicron variant to ensure maximum coverage against the virus and its known mutations.

One group of patients was given VINCOV-19, along with Standard of Care (SoC), and another group was given Standard of Care (SoC) only. VINCOV-19 showed an excellent safety profile in the phase 2 trials. There was a good and early improvement in the clinical condition of the patients administered VINCOV-19.

VINCOV-